Full Press Release Details
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR
PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
("Tiziana" or the "Company")
York/London, 7 February 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing
on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announces that
Riccardo Dalla-Favera MD has resigned from his role as Non-Executive Director of the Company. The Company is grateful to Dr Favera
for his time, expertise and commitment to the Company.
person who arranged for release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer
Tiziana Life Sciences
is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease
in oncology and immunology. In addition to milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is
the only fully human anti-CD3 mAbs in clinical development in the world. This compound has potential application in a wide range
of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative
colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable.
more information go to http://www.tizianalifesciences.com
| Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7493 2853 |
| Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner | +44 (0)20 7213 0883 |
| Stockdale Securities (Nominated broker) Antonio Bossi / Andy Crossley | +44 (0)20 7601 6125 |